Apolipoprotein A5 (APOA5) is a small protein, expressed predominantly in the liver. In plasma, it is located on triglyceride rich lipoprotein particles (chylomicrones and VLDL) and on HDL. Plasma concentration of apolipoprotein A5 is very low, suggesting rather regulatory (activation of lipoprotein lipase, …) than structural function. APOA5 is an important determinant of plasma triglyceride concentration; this effect has been confirmed both on animal models, as well as on human studies. Minor alleles of three commonly analysed variants within this gene (rs662799, rs3135506, rs2075291) are associated with higher plasma TG values and increased risk of myocardial infarction, with some important interethnic differences observed. Further roles of APOA5; determination of BMI, diabetes and last but not least nutri- and pharmaco-genetic interactions are suggested, but without the definitive conclusions.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Aberle J, Evans D, Beil FU, Seedorf U, 2005. A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet. Clin. Genet 68, 152–154. PubMed

Akhtar A, 2015. The flaws and human harms of animal experimentation. Camb. Q. Healthc. Ethics 24, 407–419. PubMed PMC

Arsenault BJ, Boekholdt SM, Kastelein JJ, 2011. Lipid parameters for measuring risk of cardiovascular disease. Nat. Rev. Cardiol 8, 197–206. PubMed

Austin MA, Talmud PJ, Farin FM, Nickerson DA, Edwards KL, Leonetti D, McNeely MJ, Viernes HM, Humphries SE, Fujimoto WY, 2004. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim. Biophys. Acta 2004, 1–9. PubMed

Beckstead JA, Oda MN, Martin DD, Forte TM, Bielicki JK, Berger T, Luty R, Kay CM, Ryan RO, 2003. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry 42, 9416–9423. PubMed

Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, Manjer J, Hallmans G, Selmer R, Almquist M, Häggström C, Engeland A, Tretli S, Concin H, Strasak A, Stattin P, Ulmer H, 2011. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 22, 291–299. PubMed

Chang SS, Wen CP, Tsai MK, Lawlor DA, Yang YC, Gunnell D, 2012. Adiposity, its related biologic risk factors, and suicide: a cohort study of 542,088 Taiwanese adults. Am. J. Epidemiol 175, 804–815. PubMed

Chasman DI, Paré G, Zee RY, Parker AN, Cook NR, Buring JE, Kwiatkowski DJ, Rose LM, Smith JD, Williams PT, Rieder MJ, Rotter JI, Nickerson DA, Krauss RM, Miletich JP, Ridker PM, 2008. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ. Cardiovasc. Genet 1, 21–30. PubMed PMC

Chiu KC, Chiu YF, Boyadjian AA, Fernando S, Kwan C, Chuang LM, 2005. Impact of apolipoprotein A5 polymorphisms on insulin sensitivity and beta-cell function. Pancreas 30, 328–332. PubMed

Do R, Stitziel NO, Won HH, Jørgensen AB, Duga S, Merlini AP, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL, NHLBI Exome Sequencing Project, Girelli D, Martinelli N, Farlow DN, DePristo MA, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, M, L., Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, Siscovick DS, McPherson R, Tybjaerg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyaev SR, O’Donnell CJ, Altshuler D, Gabriel S, Kathiresan S, 2015. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102–106. PubMed PMC

Ferreira CN, Carvalho MG, Fernandes AP, Santos IR, Rodrigues KF, Lana AM, Almeida CR, Loures-Vale AA, Gomes KB, Sousa MO, 2013. The polymorphism −1131T/C in apolipoprotein A5 gene is associated with dyslipidemia in Brazilian subjects. Gene 516, 171–175. PubMed

Forte TM, Ryan RO, 2015. Apolipoprotein A5: extracellular and intracellular roles in triglyceride metabolism. Curr. Drug Targets 16, 1274–1280. PubMed PMC

Forte TM, Shu X, Ryan RO, 2009. The ins (cell) and outs (plasma) of apolipoprotein AV. J. Lipid Res 50 (Suppl), S150–S155. PubMed PMC

Guardiola M, Alvaro A, Vallvé JC, Rosales R, Solà R, Girona J, Serra N, Duran P, Esteve E, Masana L, Ribalta J, 2012. APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate. Nutr. Metab. Cardiovasc. Dis 22, 756–762. PubMed

Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM, 2012. Pathophysiology of hypertriglyceridemia. Biochim. Biophys. Acta 2012, 826–832. PubMed

Hishida A, Morita E, Naito M, Okada R, Wakai K, Matsuo K, Nakamura K, Takashima N, Suzuki S, Takezaki T, Mikami H, Ohnaka K, Watanabe Y, Uemura H, Kubo M, Tanaka H, Hamajima N, 2012. Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study. Endocr. J 59, 589–599. PubMed

Hubacek JA, 2005. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin. Chem. Lab. Med 43, 897–902. PubMed

Hubacek JA, Skodová Z, Adámková V, Lánská V, Poledne R, 2004a. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin. Genet 65, 126–130. PubMed

Hubacek JA, Skodova Z, Adamkova V, Lanska V, Bobkova D, Poledne R, 2004b. APOAV (T-1131>C) variant has no effect on mother’s height in a large population study. Lipids Health Dis. 3, 10. PubMed PMC

Hubacek JA, Skodová Z, Adámková V, Lánská V, Poledne R, 2005a. Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol. Metabolism 54, 1632–1635. PubMed

Hubacek JA, Horínek A, Skodova Z, Adamkova V, Ceska R, Zlatohlavek L, Vráblík M, 2005b. Hypertriglyceridemia: interaction between APOE and APOAV variants. Clin. Chem 51, 1311–1313. PubMed

Hubácek JA, Skodová Z, Lánská V, Stávek P, Adámková V, Poledne R, 2005c. Apolipoprotein AV variants do not affect C-reactive protein levels in Caucasian males. Physiol. Res 54, 687–689. PubMed

Hubacek JA, Skodová Z, Adámková V, Lánská V, Pitha J, 2006. APOA5 variant Ser19Trp influences a decrease of the total cholesterol in a male 8 year cohort. Clin. Biochem 39, 133–136. PubMed

Hubacek JA, Wang WW, Skodová Z, Adámková V, Vráblík M, Horínek A, Stulc T, Ceska R, Talmud PJ, 2008a. APOA5 Ala315˃Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clin. Chem. Lab. Med 46, 773–777. PubMed

Hubacek JA, Skodová Z, Lánská V, Adámková V, 2008b. Apolipoprotein A-V variant (T-1131>C) affects plasma levels of non-high-density lipoprotein cholesterol in Caucasians. Exp. Clin. Cardiol 13, 129–132. PubMed PMC

Hubacek JA, Lánská V, Skodová Z, Adámková V, Poledne R, 2008c. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur. J. Hum. Genet 16, 135–138. PubMed

Hubácek JA, Adámková V, Vrablík M, Kadlecová M, Zicha J, Kunes J, Pitha J, Suchánek P, Poledne R, 2009a. Apolipoprotein A5 in health and disease. Physiol. Res 58 (Suppl. 2), S101–S109. PubMed

Hubacek JA, Adamkova V, Prusikova M, Snejdrlova M, Hirschfeldova K, Lanska V, Ceska R, Vrablik M, 2009b. Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics 10, 945–950. PubMed

Hubacek JA, Peasey A, Kubinova R, Pikhart H, Bobak M, 2014. The association between APOA5 haplotypes and plasma lipids is not modified by energy or fat intake: the Czech HAPIEE study. Nutr. Metab. Cardiovasc. Dis 24, 243–247. PubMed PMC

Hyun YJ, Jang Y, Chae JS, Kim JY, Paik JK, Kim SY, Yang JY, Ordovas JM, Ko YG, Lee JH, 2009. Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. Atherosclerosis 205, 568–573. PubMed PMC

Jang Y, Kim JY, Kim OY, Lee JE, Cho H, Ordovas JM, Lee JH, 2004. The −1131T˃C polymorphism in the apolipoprotein A5 gene is associated with postprandial hypertriacylglycerolemia; elevated small, dense LDL concentrations; and oxidative stress in nonobese Korean men. Am. J. Clin. Nutr 80, 832–840. PubMed

Johansen CT, Hegele RA, 2011. Genetic bases of hypertriglyceridemic phenotypes. Curr. Opin. Lipidol 22, 247–253. PubMed

Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-Melander M, 2008. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet 40, 189–197. PubMed PMC

Ken-Dror G, Goldbourt U, Dankner R, 2010. Different effects of apolipoprotein A5 SNPs and haplotypes on triglyceride concentration in three ethnic origins. J. Hum. Genet 55, 300–307. PubMed

Khovidhunkit W, Duchateau PN, Medzihradszky KF, Moser AH, Naya-Vigne J, Shigenaga JK, Kane JP, Grunfeld C, Feingold KR, 2004. Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis 176, 37–44. PubMed

Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X, Ordovas JM, 2003. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J. Lipid Res 44, 2365–2373. PubMed

Lai CQ, Corella D, Demissie S, Cupples LA, Adiconis X, Zhu Y, Parnell LD, Tucker KL, Ordovas JM, 2006. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. Circulation 113, 2062–2070. PubMed

Langley G, 2009. The validity of animal experiments in medicine research. RSDA. 1, 161–168.

Laurila PP, Naukkarinen J, Kristiansson K, Ripatti S, Kauttu T, Silander K, Salomaa V, Perola M, Karhunen PJ, Barter PJ, Ehnholm C, Peltonen L, 2010. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler. Thromb. Vasc. Biol 30, 346–352. PubMed PMC

Lee KH, Kim OY, Lim HH, Lee YJ, Jang Y, Lee JH, 2010. Contribution of APOA5–1131C allele to the increased susceptibility of diabetes mellitus in association with higher triglyceride in Korean women. Metabolism 59, 1583–1590. PubMed

Li Y, He PP, Zhang DW, Zheng XL, Cayabyab FS, Yin WD, Tang CK, 2014. Lipoprotein lipase: from gene to atherosclerosis. Atherosclerosis 237, 597–608. PubMed

Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK, 2009. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet. Genomics 19, 161–169. PubMed PMC

Liu CF, Yang QF, Chen XL, Liu CY, 2012. Apolipoprotein a5 gene polymorphism and risk for metabolic syndrome: a meta-analysis. Genet. Test Mol. Biomarkers. 16, 1241–1245. PubMed

Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, Chen YM, 2013. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis. 12, 159. PubMed PMC

Manpuya MW, Guo J, Zhao Y, 2001. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin. Med. J. 114, 275–279 Engl. PubMed

Martić-Kehl MI, Schibli R, Schubiger PA, 2012. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur. J. Nucl. Med. Mol. Imaging 39, 1492–1496. PubMed PMC

Martín-Campos JM, Rico N, Bonet R, Mayoral C, Ordóñez-Llanos J, Blanco-Vaca F, 2006. Apolipoprotein A5S19W may play a role in dysbetalipoproteinemia in patients with the Apo E2/E2 genotype. Clin. Chem 52, 1974–1975. PubMed

Mattei J, Demissie S, Tucker KL, Ordovas JM, 2009. Apolipoprotein A5 polymorphisms interact with total dietary fat intake in association with markers of metabolic syndrome in Puerto Rican older adults. J. Nutr 139, 2301–2308. PubMed PMC

Melegh BI, Duga B, Sümegi K, Kisfali P, Maász A, Komlósi K, Hadzsiev K, Komoly S, Kosztolányi G, Melegh B, 2012. Mutations of the apolipoprotein A5 gene with inherited hypertriglyceridaemia: review of the current literature. Curr. Med. Chem 19, 6163–6170. PubMed

Merkel M, Heeren J, 2005. Give me A5 for lipoprotein hydrolysis! J. Clin. Invest 115, 2694–2696. PubMed PMC

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, 2011. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 123, 2292–2333. PubMed

Navaneethan SD, Schold JD, Arrigain S, Thomas G, Jolly SE, Poggio ED, Schreiber MJ Jr., Sarnak MJ, Nally JV Jr., 2012. Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease. Nephrol. Dial. Transplant 27, 3228–3234. PubMed PMC

Ngaosuwan K, Houngngam N, Limpisook P, Plengpanich W, Khovidhunkit W, 2015. Apolipoprotein A-V is not a major determinant of triglyceride levels during human sepsis. J. Crit. Care 30, 727–731. PubMed

Nilsson SK, Lookene A, Beckstead JA, Gliemann J, Ryan RO, Olivecrona G, 2007. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 46, 3896–3904. PubMed

Nilsson SK, Heeren J, Olivecrona G, Merkel M, 2011. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis 219, 15–21. PubMed

Novotny D, Karasek D, Vaverkova H, Slavik L, 2014. The influence of apolipoprotein A5T-1131C and apolipoprotein E common genetic variants on the levels of hemostatic markers in dyslipidemic patients. Clin. Chim. Acta 436, 11–17. PubMed

O’Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ, 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem 51, 351–359. PubMed

Park JY, Paik JK, Kim OY, Chae JS, Jang Y, Lee JH, 2010. Interactions between the APOA5 −1131T˃C and the FEN1 10154G˃T polymorphisms on ω6 polyunsaturated fatty acids in serum phospholipids and coronary artery disease. J. Lipid Res 51, 3281–3288. PubMed PMC

Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM, 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169–173. PubMed

Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC, 2002. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet 11, 3031–3038. PubMed

Pikhart H, Hubáček JA, Peasey A, Kubínová R, Bobák M, 2015. Association between fasting plasma triglycerides, all-cause and cardiovascular mortality in Czech population. Results from the HAPIEE study. M. Physiol Res 64 (Suppl. 3), S355–S361. PubMed

Sánchez-Moreno C, Ordovás JM, Smith CE, Baraza JC, Lee YC, Garaulet M, 2011. APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population. J. Nutr 141, 380–385. PubMed PMC

Schaap FG, Nierman MC, Berbée JF, Hattori H, Talmud PJ, Vaessen SF, Rensen PC, Chamuleau RA, Kuivenhoven JA, Groen AK, 2006. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J. Lipid Res 47, 2333–2339. PubMed

Schaefer JR, Sattler AM, Hackler B, Kurt B, Hackler R, Maisch B, Soufi M, 2004. Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5S19W mutation as a cofactor. Clin. Chem 50, 2214. PubMed

Schwarzova L, Hubacek JA, Vrablik M, 2015. Genetic predisposition of human plasma triglyceride concentrations. Physiol. Res 64 (Suppl. 3), S341–S354. PubMed

Shu X, Chan J, Ryan RO, Forte TM, 2007. Apolipoprotein A-V association with intracellular lipid droplets. J. Lipid Res 48, 1445–1450. PubMed

Shu X, Nelbach L, Ryan RO, Forte TM, 2010. Apolipoprotein A-V associated with intrahepatic lipid droplets and influences triglyceride accumulation. Biochim. Biophys. Acta 2010, 605–608. PubMed PMC

Smith CE, Tucker KL, Lai CQ, Parnell LD, Lee YC, Ordovás JM, 2010. Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin. Obesity (Silver Spring) 18, 327–332. PubMed PMC

Suchanek P, Lorenzova A, Poledne R, Hubacek JA, 2008. Changes of plasma lipids during weight reduction in females depends on APOA5 variants. Ann. Nutr. Metab 53, 104–108. PubMed

Talmud PJ, 2001. Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr. Atheroscler. Rep 3, 191–199. PubMed

Talmud PJ, Cooper JA, Hattori H, Miller IP, Miller GJ, Humphries SE, 2006. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 49, 2337–2340. PubMed

Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, 2010g. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 375, 1634–1639 (Erratum in: Lancet. 2010;376:90. Kastelein, J J [added]). PubMed PMC

van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA, 2001. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem 276, 44512–44520. PubMed

Vrablik M, Hubacek JA, 2010. Genetic determination of triglyceridemia with special focus on apolipoprotein gene variants. Clin. Lipidol 5, 543–554.

Wang MH, Li J, Yeung VS, Zee BC, Yu RH, Ho S, Waye MM, 2014. Four pairs of gene-gene interactions associated with increased risk for type 2 diabetes (CDKN2BAS-KCNJ11), obesity (SLC2A9-IGF2BP2, FTO-APOA5), and hypertension (MC4R-IGF2BP2) in Chinese women. Meta Gene. 2, 384–391. PubMed PMC

Ward KJ, Shields B, Knight B, Salzmann MB, Hattersley AT, Frayling TM, 2003. Genetic variants in Apolipoprotein AV alter triglyceride concentrations in pregnancy. Lipids Health Dis. 2, 9. PubMed PMC

Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, Aulchenko YS, Zhang W, Yuan X, Lim N, Luan J, Ashford S, Wheeler E, Young EH, Hadley D, Thompson JR, Braund PS, Johnson T, Struchalin M, Surakka I, Luben R, Khaw KT, Rodwell SA, Loos RJ, Boekholdt SM, Inouye M, Deloukas P, Elliott P, Schlessinger D, Sanna S, Scuteri A, Jackson A, Mohlke KL, Tuomilehto J, Roberts R, Stewart A, Kesäniemi YA, Mahley RW, Grundy SM, Wellcome Trust Case Control Consortium, McArdle W, Cardon L, Waeber G, Vollenweider P, Chambers JC, Boehnke M, Abecasis GR, Salomaa V, Järvelin MR, Ruokonen A, Barroso I, Epstein SE, Hakonarson HH, Rader DJ, Reilly MP, Witteman JC, Hall AS, Samani NJ, Strachan DP, Barter P, van Duijn CM, Kooner JS, Peltonen L, Wareham NJ, McPherson R, Mooser V, Sandhu MS, 2010. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc. Biol 30, 2264–2276. PubMed PMC

Xu C, Bai R, Zhang D, Li Z, Zhu H, Lai M, Zhu Y, 2013. Effects of APOA5 −1131T˃C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis. PLoS One 8, e56216. PubMed PMC

Yang Y, Walijee SM, Jin J, Zhao SP, Peng DQ, 2012. Serum apolipoprotein A-V in patients with coronary artery disease and its association with triglyceride. J. Clin. Lipidol 6, 462–468. PubMed

Yin YW, Sun QQ, Wang PJ, Qiao L, Hu AM, Liu HL, Wang Q, Hou ZZ, 2014. Genetic polymorphism of apolipoprotein A5 gene and susceptibility to type 2 diabetes mellitus: a meta-analysis of 15,137 subjects. PLoS One 9, e89167. PubMed PMC

Zaki M, Amr K, 2014. Apolipoprotein A5T-1131C variant and risk for metabolic syndrome in obese adolescents. Gene 534, 44–47. PubMed

Zheng XY, Zhao SP, Yu BL, Wu CL, Liu L, 2012. Apolipoprotein A5 internalized by human adipocytes modulates cellular triglyceride content. Biol. Chem 393, 161–167. PubMed

Zlatohlavek L, Vrablik M, Ceska R, Adamkova V, Urbanova Z, Prusikova M, Vasickova L, Hubacek JA, 2012. APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children. Nutr. Metab. Cardiovasc. Dis 22, e22–e23. PubMed

Cholesterol associated genetic risk score and acute coronary syndrome in Czech males

Genetics of Cardiovascular Disease: How Far Are We from Personalized CVD Risk Prediction and Management?

The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Case-Control Study